BPC-157 and TB-500 together: what is known about the pair

People who search for BPC-157 and TB-500 together usually want to know whether the pair heals injuries faster than either alone. The short verdict is that nobody has shown that in a human being, and the one controlled experiment that tested it, in rats, says no. FDA found no human data on TB-500 at all. Neither peptide is FDA-approved, and a vial containing both falls outside the interim HHS compounding policy.

What the evidence covers, at a glance

The calculator does vial arithmetic only. No human dose of either peptide has been established, and BPC-157 dosage explains why rat doses do not convert.

Does combining them work better?

The best available answer is no, with low confidence, in rats. In a 2026 experiment from Istanbul, 32 rats had their Achilles tendons cut and repaired, then received one of four treatments by injection into the abdomen for four weeks: saline, BPC-157 at 10 mcg/kg a day, TB-500 at 60 mcg/kg a day, or both.

• TB-500 alone produced a statistically significant gain in tendon strength over controls. BPC-157 alone produced a smaller gain that did not reach significance.
• Tissue scores were better in the TB-500 and combination groups.
• The authors’ conclusion: “Combined BPC-157 and TB-500 treatment did not confer additional benefits compared to either agent alone.”

That is one small, exploratory study with eight rats per group. It does not show the combination works in people, and its main finding is that combining them added nothing.

The nearest thing to human data is a 2021 retrospective review of knee injections at a Florida clinic. Of 16 patients reached by phone, 4 had received BPC-157 with thymosin beta-4, and 3 of those 4 reported improvement. There was no control group, the injections went into the knee, and the paper describes thymosin beta-4 rather than TB-500. Four people cannot tell you anything about a combination.

Why do people pair them?

The idea is that two peptides acting differently might add up. BPC-157 is proposed to work through growth factors and blood vessels, and thymosin beta-4 through actin and cell migration. That rationale stitches together separate lab and animal findings, much of it about the larger thymosin beta-4 protein and not TB-500. Use is real, though. In a preprint of clinical notes reported by AJMC in October 2026, TB-500 was among the most common agents taken alongside BPC-157. Those records cannot tell us whether the pairing helps.

What TB-500 is, and what it is not

Thymosin beta-4 is a natural protein of 43 amino acids. TB-500 is something smaller: FDA’s July 2026 review describes it as “understood today to be a seven amino acid synthetic fragment,” amino acids 17 to 23 with an acetyl group added. Three points matter to anyone reading a label:

• TB-500 is not thymosin beta-4. FDA states that “thymosin beta-4 and TB-500 are not the same substance.” Human trial results for the full protein, mostly eye drops and skin gels, do not apply to the fragment.
• The name is not standardized. FDA has “encountered multiple salts, and derivatives, including different active moieties, sold commercially under the same common name.”
• Products do not match their labels. A 2023 laboratory analysis of products sold online as TB500 and TB1000 found their content was “not systematically consistent” with their descriptions.

The TB-500 guide has the full trial table and the claims.

Where the “Wolverine” name comes from

“Wolverine stack” or “Wolverine protocol” is a seller and forum name for the pair, borrowed from the comic-book character who heals quickly. FDA’s 2026 review cites seller pages that use the phrase. It is a marketing term, and no trial has tested it as a regimen. The Wolverine stack page covers the claims.

Safety: what FDA found

FDA searched its adverse event databases for both peptides before the July 2026 meeting.

• TB-500: no reports in FDA’s drug adverse event database (FAERS) through March 2025, and no case reports in the literature. FDA’s food and supplement database held two reports about “blended TB-500 and BPC-157” with no safety assessment. FDA concluded that “potential safety risks associated with the use of TB-500 in humans are unknown” and raised concern about immunogenicity, an immune reaction against the peptide, with injected peptides.
• BPC-157 plus TB-500: one FAERS report described a 40-year-old woman who injected a blended product labeled for research purposes only, twice daily, and developed diffuse darkening of the skin and gums. The reaction recurred when she used the product again two weeks later and stopped when she quit. FDA said that because the product contained two peptides, it could not assess which caused it.

Absence of reports is not evidence of safety. FDA notes that reporting is voluntary and that compounders under 503A generally do not report adverse events. Risks that apply to each peptide, such as the clotting and liver signals in BPC-157 animal studies, are in the BPC-157 side effects guide.

FDA status of both peptides

Does the HHS policy cover the combination?

No. As of November 2, 2026, HHS says it does not intend to take enforcement action against compounding of either peptide when all ten conditions are met, and one condition is that the product contains a single active ingredient. A blend sits outside the policy even though both ingredients are on the list. HHS gave its reason: with a single ingredient, “it will be easier to attribute adverse events or clinical outcomes to a specific substance.” The darkening case above is what that looks like in practice.

The policy is silent on someone prescribed two separate single-peptide products, and no study has looked at that either. Silence is not permission, and we are not suggesting it as a workaround.

Neither peptide becomes approved under this policy. Neither is on the 503A bulks list, FDA has not reviewed any compounded product, and the notice says it is “not binding on HHS or the public.” HHS may revisit it if a safety signal or quality problem appears, and states can be stricter. FDA’s reasons for proposing against TB-500 still stand as a description of the evidence: no human data by any route, no toxicity studies, unclear historical use and approved wound treatments already available. The FDA status tracker follows the rulemaking.

WADA status

The 2026 WADA Prohibited List, in force from January 1, 2026, names BPC-157 under class S0 (non-approved substances) and lists “Thymosin-β4 and its derivatives e.g. TB-500” under class S2.3 (growth factors and growth factor modulators). Both classes are prohibited at all times, in and out of competition.

What research use only means for this pair

Much of what is sold online, including pre-mixed blends, carries a “research use only” label. Those products are not legal to use on people, and the HHS policy gives them no cover: 21 CFR 312.160 allows shipment only for tests in laboratory animals or test tubes, and FDA warning letters have said the disclaimer does not protect sellers whose marketing targets people. The reported reaction above came from exactly this kind of product, and nobody had checked what was in the vial.